This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Ophthalmological Procedures, Other  • Alert me on articles by topic

Arch Ophthalmol. 2005;123:1008-1012.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Germline retinoblastoma results from a somatic mutation involving loss or inactivation of the tumor suppressor gene located at 13q14.¹ Absence of gene activity predisposes to retinoblastoma and other tumor development.^1-2 The introduction of chemotherapy protocols with focal consolidation therapy has enhanced our ability to treat germline retinoblastoma while salvaging many eyes that would have been lost previously.^3-8 A secondary benefit has been that we are now preserving eyes with useful vision. However, because of the aggressive, multimodal therapy involved, patients often develop intraocular complications. We evaluated a group of patients who had undergone enucleation for retinoblastoma in one eye with salvage of the other eye and who had maintained tumor quiescence for a period of 12 months or longer in that eye. Our purpose was to determine how these patients fared following intraocular surgery of the salvaged eye.

Patients and Methods

We performed a retrospective review of all germline retinoblastoma cases from January . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION
Darius M. Moshfeghi, MD; Matthew W. Wilson, MD; Sanderson Grizzard, MD; Barrett G. Haik, MD